Obesity: pathophysiology and related therapeutic strategies

• Grant number: 19/25493-6
• Support Opportunities: Research Projects - Thematic Grants
• Start date: June 01, 2022
• End date: May 31, 2027
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Marcelo Costa Batista
• Grantee: Marcelo Costa Batista
• Host Institution: Escola Paulista de Medicina (EPM). Universidade Federal de São Paulo (UNIFESP). Campus São Paulo. São Paulo , SP, Brazil
• City of the host institution: São Paulo
• Principal investigators: Maria Teresa Zanella
• Associated researchers: Beata Marie Redublo Quinto ; Glaucia Carneiro ; Luiz Vicente Rizzo ; Maria Aparecida Dalboni ; Mário Luís Ribeiro Cesaretti ; Mark Sarnak
• Associated scholarship(s): 24/19151-3 - Study of microRNAS in the genesis of endothelial injury resulting from oxygen deprivation and impact of treatment with GLP-1 analogue (GLUCAGON - LIKE PEPTIDE 1) in association with SGLT2 inhibitors, BP.DD; 24/09554-3 - EVALUATION OF TREATMENT WITH LIRAGLUTIDE AND SGLT2 INHIBITORS IN THE MODULATION OF MRNAS 21, 145 AND 34A THROUGH THE HIF1-A SIGNALING PATHWAY IN PROXIMAL CELLS (HK-2) SUBJECT TO OXYGEN DEPRIVATION, BP.IC; 24/06309-8 - Evaluation of treatment with liraglutide and SGLT2 inhibitors in inflammation mediated by the action of microRNAS 21, 145 and 34A on the HIF1-alpha factor in proximal cells (HK-2) subject to oxygen deprivation, BP.DD; + associated scholarships 23/16578-3 - STUDY OF MICRORNAS IN THE GENESIS OF ENDOTHELIAL INJURY RESULTING FROM OXYGEN DEPRIVATION AND IMPACT OF TREATMENT WITH GLP 1 ANALOGUE (GLUCAGON-LIKE PEPTIDE 1) IN ASSOCIATION WITH SGLT2 INHIBITORS, BP.IC; 23/10378-2 - Effect of stem cell derived from adipose tissue on mirnas 126 and 21 in SHR rats induced visceral obesity, BP.IC; 22/08798-0 - EVALUATION OF TREATMENT WITH LIRAGLUTIDE AND SGLT2 INHIBITORS IN INFLAMMATION MEDIATED BY THE ACTION OF microRNAS 21, 145 AND 34A ON The HIF1-ALPHA FACTOR IN PROXIMAL CELLS (HK-2) SUBMITTED TO OXYGEN DEPRIVATION., BP.MS; 22/08828-7 - STUDY OF MICRORNAS IN THE GENESIS OF ENDOTHELIAL DAMAGE RESULTING FROM OXYGEN DEPRIVATION AND IMPACT OF TREATMENT WITH GLP-1 ANALOG (GLUCAGON-LIKE PEPTIDE 1) IN ASSOCIATION WITH SGLT2 INHIBITORS, BP.MS; 23/01434-6 - OBESITY: PATHOPHYSIOLOGY AND RELATED THERAPEUTIC STRATEGIES, BP.PD; 23/01052-6 - Study of Innate Immunity and Epigenetic Regulation in the Endothelial Lessons of Obese Patients Treated with a Sodium/Glucose Cotransporter Type 2 Inhibitor: A Cross-Randomized Study, BP.TT; 22/09481-0 - EFFECT OF THE GLUCAGON-LIKE PEPTIDE 1 (GLP1) AGONIST LIRAGLUTIDE, ON BLOOD PRESSURE, GLUCOSE METABOLISM AND MODULATION OF TUBULAR FUNCTION AS MEASURED BY MICRORNAS IN AN EXPERIMENTAL MODEL OF HYPERTENSION AND INSULIN., BP.MS; 22/09850-6 - EFFECT OF DAPAGLIFLOZIN TREATMENT ON THE EXPRESSION OF MIRCRORNAS 126 AND 21 IN SPONTANEOUSLY HYPERTENSIVE RATS SUBMITTED TO A HYPERCALORIC DIET, BP.IC - associated scholarships

Abstract

The obesity epidemic and the resulting burden of cardiovascular events and renal disease have led to an unfavorable impact on global public health. These events are in close association with risk factors arising from changes in lipid metabolism, diabetes mellitus and hypertension, which has generated great interest in the scientific community in recent years. Therefore, the search for interventions through different therapeutic strategies, with emphasis on the study of cellular and molecular pathways and the development of common biomarkers as well, has been the premise of many research areas. With this perception, the Research Group of the Nephrology Division of Universidade Federal de São Paulo in association with researchers at the Nephrology Division of Tufts University in Boston and the Academic Research Organization of Hospital Israelita Albert Einstein made a collective effort to develop the Project: "Obesity: pathophysiology and related therapeutic strategies." We are aiming at a translational approach, covering different subprojects in areas of cellular and molecular biology, in clinical protocols as well as experimental models with common interfaces. In this Thematic Project, involving 2 Principal Investigators and 5 Associates along with the participation of 12 fellows (Scientific Initiation and Postdoctoral) and students (Master's and Doctorate), we focused on the search for a therapeutic standpoint (including pharmacological treatment, bariatric surgery and stem cell therapy) under the pathophysiological mechanisms common to visceral obesity such as inflammation-generating hypoxia, modulation of gene expression patterns in response to environmental stimuli, and changes in immune response in several cellular and experimental models in 10 subprojects. (AU)